SPRY Earnings Date & History
ARS Pharmaceuticals Inc (NASDAQ NMS - GLOBAL MARKET) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 7:17 PM ET
ARS Pharmaceuticals Inc
Biotechnology
- Next earnings date
- Monday, November 9, 2026
- Reporting session
- After Close
- EPS estimate
- $-0.30
- Revenue estimate
- $50.9M
SPRY earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Thursday, August 13, 2026 | Q2 2026 | $-0.50 | $-0.63 | -25.4% | $33.7M |
| Friday, May 15, 2026 | Q1 2026 | $-0.54 | $-0.61 | -13.8% | $22.7M |
| Monday, March 9, 2026 | Q4 2025 | $-0.45 | $-0.42 | +6.8% | $28.1M |
| Monday, November 10, 2025 | Q3 2025 | $-0.48 | $-0.52 | -8.0% | $32.5M |
| Wednesday, August 13, 2025 | Q2 2025 | $-0.48 | $-0.46 | +4.0% | $15.7M |
What the market is watching in SPRY's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next SPRY earnings date?
- ARS Pharmaceuticals Inc is scheduled to report on Monday, November 9, 2026 (After Close). Dates can change until the company confirms them.
- Does SPRY report before or after the market?
- The next report is scheduled after close.
- What EPS is expected for SPRY?
- Consensus EPS for the upcoming quarter is $-0.30, on revenue of $50.9M.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
SPRY earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.